Wild, Wild West of Cannabidiol (CBD): Is it Possible to Hold CBD to the Same Standards as Other Medicines to Protect Consumers, Patients, and Clinicians

9:00 AM - 10:15 AM, Thursday, June 11, 2020 ・ Room 2
Currently, companies are creating a myriad of CBD products largely unburdened by any oversight or testing requirements. The inherent complexity of CBD, combined with the danger of hazardous additives, raises serious public health concerns that absent some rules or regulations, unscrupulous companies will be able to distribute products that include illegal CBD combinations or have dangerous additives. Despite a dearth of reliable scientific evidence, the belief in efficacy, fueled by pseudoscience, testimonials, media reporting of same, has resulted in a torrent of interest in cannabis not just as a wellness product but as a medicine for serious conditions. Consumers, including patients, clinicians, and researchers, are acutely interested in understanding if and how CBD can be used safely and effectively to address unmet health issues.
UNC School of Medicine; Director of Clinical Integration, Angelman Syndrome Foundation
UNC; Angelman Syndrome Foundation
Executive Director
Anxiety and Depression Association of America
Principal Investigator & Asst Professor of Psychiatry
Veterans Affairs San Diego Healthcare System; UC San Diego School of Medicine
Vice President, U.S. Public Policy and Public Affairs
Greenwich Biosciences